Melanóma: vizsgálatok itt: Románia
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peoplePharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Biocon Biologics UK PLC
See details and how to joinNCT07476326 · EU 2025-525158-20-00 - 3. fázisTaking peopleStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- Where
- Craiova
- Életkor
- 18 év and over
- People
- 632 worldwide
- Run by
- mAbxience Research S.L.
See details and how to joinNCT07221734 - 1. fázisTaking peopleA PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
- Where
- Bucharest, Cluj-Napoca, Craiova, Timisoara, Timișoara
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- H e x a l AG
See details and how to join2025-521919-39-00 · EU 2025-521919-39-00 - 1. fázisTaking peoplePharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Alvotech Swiss AG
See details and how to joinNCT07475572 · EU 2025-525093-11-00 - 3. fázisTaking peopleRandomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
- Where
- Craiova
- Életkor
- 18 év and over
- People
- 119 worldwide
- Run by
- Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00 - 1. fázisTaking peopleA Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- Celltrion Inc.
See details and how to join2023-510017-26-00 · EU 2023-510017-26-00 - 3. fázisTaking peopleIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- Cluj-Napoca, Craiova, Iași
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314 - 1. fázisTaking peopleA Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 34 worldwide
- Run by
- Intas Pharmaceuticals Limited
See details and how to join2025-522307-14-00 · EU 2025-522307-14-00